Meyers FJ - Search Results

1

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

O'Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN, Griffith IJ, Goldstein DS, Kukis DL, Martinez GS, Mirick GR, DeNardo GL, Meyers FJ. O'Donnell RT, et al. Among authors: meyers fj. Clin Cancer Res. 2001 Jun;7(6):1561-8. Clin Cancer Res. 2001. PMID: 11410491 Clinical Trial.

2

Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.

DeNardo GL, Kukis DL, DeNardo SJ, Shen S, Mausner LF, O'Donnell RT, Lamborn KR, Meyers FJ, Srivastava SC, Miers LA. DeNardo GL, et al. Among authors: meyers fj. Cancer. 1997 Dec 15;80(12 Suppl):2576-82. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2576::aid-cncr33>3.3.co;2-3. Cancer. 1997. PMID: 9406712

3

L6 monoclonal antibody binds prostate cancer.

O'Donnell RT, DeNardo SJ, Shi XB, Mirick GR, DeNardo GL, Kroger LA, Meyers FJ. O'Donnell RT, et al. Among authors: meyers fj. Prostate. 1998 Oct 1;37(2):91-7. doi: 10.1002/(sici)1097-0045(19981001)37:2<91::aid-pros5>3.0.co;2-o. Prostate. 1998. PMID: 9759703

4

Treatment options in androgen-independent prostate cancer.

Lara PN Jr, Meyers FJ. Lara PN Jr, et al. Among authors: meyers fj. Cancer Invest. 1999;17(2):137-44. Cancer Invest. 1999. PMID: 10071598 Review.

5

Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.

O'Donnell RT, DeNardo SJ, DeNardo GL, Miers L, Lamborn KR, Kukis DL, Meyers FJ. O'Donnell RT, et al. Among authors: meyers fj. Prostate. 2000 Aug 1;44(3):187-92. doi: 10.1002/1097-0045(20000801)44:3<187::aid-pros2>3.0.co;2-c. Prostate. 2000. PMID: 10906734

6

Development of monoclonal antibody imaging of metastatic prostatic carcinoma.

Meyers FJ, Denardo SJ, Macey D, White RD, Unger M. Meyers FJ, et al. Prostate. 1989;14(3):209-20. doi: 10.1002/pros.2990140303. Prostate. 1989. PMID: 2471962

7

Molecular biology of prostate carcinogenesis.

Lara PN Jr, Kung HJ, Gumerlock PH, Meyers FJ. Lara PN Jr, et al. Among authors: meyers fj. Crit Rev Oncol Hematol. 1999 Dec;32(3):197-208. doi: 10.1016/s1040-8428(99)00041-4. Crit Rev Oncol Hematol. 1999. PMID: 10633849 Review. No abstract available.

8

Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.

Meyers FJ, O' Donnell RT. Meyers FJ, et al. Clin Cancer Res. 2000 Oct;6(10):4167. Clin Cancer Res. 2000. PMID: 11051273 No abstract available.

9

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Lara PN Jr, et al. Among authors: meyers fj. J Clin Oncol. 2001 Mar 15;19(6):1728-33. doi: 10.1200/JCO.2001.19.6.1728. J Clin Oncol. 2001. PMID: 11251003

10

A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell carcinoma.

O'Donnell RT, Dea G, Meyers FJ. O'Donnell RT, et al. Among authors: meyers fj. J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):58-61. doi: 10.1097/00002371-199501000-00007. J Immunother Emphasis Tumor Immunol. 1995. PMID: 7728306 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters